RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products, according to the company’s website (see here: www.RegeneRx.com). SNNLive caught up with J.J. Finkelstein, President & CEO of RegeneRx Biopharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY.
“We have four (4) late-stage clinical trials in the field of ophthalmology that are getting ready to start this year. They will take about 6-9 months to enroll patients and accumulate data, and we’re looking forward to a really productive outcome with RGN-259, our ophthalmic eye-drops,” Mr. Finkelstein begins. He continues with a discussion of how their drug candidate is looking to treat various conditions associated of the eye, and what about their treatment for eye conditions is similar to stem cell therapies are trying to do.
Mr. Finkelstein goes on to talk about the other indications the company is working on the cardiac and dermal spaces, where the Company’s science comes from, and his insights into 2015-2016 for the RegeneRx.
Since speaking with Mr. Finkelstein, the company has made the following announcements:
For more information about RegeneRx Biopharmaceuticals, Inc., go to: www.RegeneRx.com
© 2017 Stock News Now
Supported by Superior Web Solutions